Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Professional Essentials · Free · No registration

Critical Digital Ischemia

Recognize threatened tissue, organize vascular and rheumatology rescue, check vasodilator hazards and follow perfusion through recovery.

Clinically reviewed: October 4, 2026 · Free to read · English

1. Recognize threatened tissue

Critical digital ischemia is a tissue-threatening emergency, not simply a more uncomfortable Raynaud attack. Suspect it when a digit remains cold or discolored, pain persists at rest, gentle warming does not restore the usual baseline, or new ulceration, necrosis, numbness or weakness appears. Rapid deterioration, neurological change or extension into the hand requires immediate hospital assessment and early vascular or hand-surgical involvement.

The 2024 BSR systemic sclerosis guideline identifies new necrosis or critical ischemia as an emergency. Its preference for assessment within 48 hours must not be interpreted as permission to observe an actively threatened digit at home. Severity and progression determine the immediate response.

Compare with the patient’s ordinary episodes and previous wounds. A chronic dry lesion and a newly deteriorating fingertip have different implications, but either may develop superimposed infection. Palpable wrist pulses do not establish adequate digital perfusion. Color can be difficult to interpret across skin tones and lighting; temperature, sensation, movement and the trajectory remain essential.

Recognizing critical digital ischemia → Professional access required

2. Assess and protect the digit

Assess systemic stability while examining both hands. Record onset, progression, individual digits, rest pain, temperature, color, capillary refill, active movement, sensation, radial and ulnar pulses, and available Doppler signals. Describe wounds separately from perfusion. Look for purulence, spreading erythema, exposed tissue or bone, and systemic infection. Record timed findings so subsequent clinicians can recognize change.

Provide a warm environment, gentle protection and adequate analgesia. Avoid direct heating or tight dressings, and relieve rings or other constriction safely. A photograph with appropriate clinical consent can document appearance, but cannot determine viability. Arrange intravenous access and appropriate blood count, platelets, renal function and coagulation studies while the rescue pathway proceeds.

In an outpatient setting, contact the receiving service directly and arrange emergency transfer when indicated. Specify who has accepted the patient and what monitoring is needed during transfer. State the immediate clinical question in the handoff: threatened perfusion, possible arterial obstruction, concurrent infection, or a combination. Report the last documented normal sensation and movement, not only the time the patient first noticed a color change. Share existing arterial studies and previous rescue responses while recognizing that an old result cannot describe today’s circulation. Diagnostic uncertainty is a reason for urgent assessment, not a reason to wait for an autoimmune panel. Document recent medication doses and any intervention already attempted.

Initial assessment and disposition → Professional access required

3. Identify the mechanism in parallel

Systemic sclerosis vasculopathy can coexist with a treatable arterial occlusion. Abrupt, markedly asymmetric ischemia, pulse changes, an embolic source or a recent arterial procedure should accelerate vascular assessment. Duplex or other arterial imaging should answer whether there is an actionable lesion and must be coordinated with treatment urgency.

Other possibilities include vasculitis, cryoglobulinemic disease, antiphospholipid-associated thrombosis, infection, trauma, vasopressor exposure and constriction. Select investigations from the clinical pattern: urinalysis and renal function for systemic vasculitis, relevant serology, embolic-source evaluation, or microbiology and imaging for deep infection. Antibody positivity alone does not establish antiphospholipid syndrome.

The ESVS acute limb ischemia guideline recommends heparin while awaiting revascularization. Application to an individual ischemic finger requires a vascular decision about the suspected mechanism, bleeding risk, platelet count, previous heparin-induced thrombocytopenia and procedural plan. Anticoagulation is not an automatic treatment for every systemic sclerosis ulcer. Infection and impaired perfusion may require simultaneous antibiotics, source control and vascular rescue.

Competing and overlapping causes → Professional access required

4. Use mechanism-directed rescue

Ongoing critical ischemia needs an active specialist rescue plan. Increasing oral vasodilators while waiting for improvement is insufficient when tissue remains threatened. For severe systemic sclerosis-related vasculopathy, monitored intravenous prostanoid treatment may be appropriate; an amenable arterial lesion may instead require intervention, or both approaches may be needed.

EULAR systemic sclerosis recommendations distinguish treatment roles: calcium-channel blockers and PDE5 inhibitors address Raynaud manifestations; intravenous iloprost and PDE5 inhibitors are considered for digital-ulcer treatment; bosentan reduces new ulcers in selected patients. Prevention of another ulcer should not be presented as immediate reversal of an ischemic crisis.

The evidence for chronic ulcer outcomes also needs context. In SEDUCE, sildenafil did not significantly improve the primary time-to-healing endpoint, although secondary ulcer outcomes favored treatment. This does not establish a universal acute salvage regimen. Selected refractory disease may warrant surgical approaches, but the initial priority remains viable tissue and timely reassessment. Availability, approval and infusion practice differ by jurisdiction. If the required service is unavailable locally, discuss transfer early with a center able to provide vascular assessment, monitored treatment and specialist wound care. A referral should identify the missing capability and the immediate plan while transport is arranged.

Rescue options and their limits → Professional access required

5. Reconcile vasodilator hazards

The UK intravenous iloprost product information requires dilution, controlled infusion and monitoring of blood pressure and pulse during initiation and dose increases. The regimen must follow the actual formulation, indication, organ function and local pharmacy protocol. Review bleeding and cardiovascular risk, pregnancy status and concurrent vasoactive treatment; significant hypotension or other toxicity requires prompt adjustment.

Never substitute an inhaled preparation or another indication’s dosing instructions for a verified intravenous protocol. A patient already receiving pulmonary-hypertension treatment needs specialist reconciliation before an additional vasodilator is prescribed. Document the pump, concentration, route and responsible team where an infusion is used.

Sildenafil labeling contraindicates combination with organic nitrates or riociguat. Nitroglycerin ointment, patches and as-needed sprays count: ask about every route and recent dose. Riociguat also has important nitrate and PDE5-inhibitor restrictions. A medication list that omits occasional or pulmonary-hypertension drugs is incomplete. Switching intervals require drug-specific review; simply separating administration times does not establish safety.

Selected medication-safety checks → Professional access required

6. Follow perfusion through recovery

Repeat the same neurovascular examination after interventions and whenever symptoms change. Less pain may reflect analgesia or new sensory loss rather than improved perfusion. A colder digit, spreading discoloration, declining movement or worsening Doppler findings requires immediate escalation. During vasodilator treatment, monitor systemic tolerance alongside the local examination.

Spreading infection, wet necrosis, fever or instability requires urgent surgical and infection assessment. Do not apply a blanket rule to wait for demarcation when source control is needed. Likewise, systemic glucocorticoids are not routine rescue for systemic sclerosis vasculopathy; if a separate inflammatory vasculitis is suspected, treatment requires a cause-specific decision with attention to renal-crisis risk.

Before transition from acute care, establish sustained improvement, an explicit wound plan, medication ownership and timely specialist review. Discuss protection from cold and trauma, smoking cessation where relevant, and instructions for new rest pain, sensory change or infection. Record functional consequences and arrange hand therapy or occupational support when appropriate. Recovery is measured by preserved tissue and function, not pain relief alone.

Sources and clinical verification

Clinically reviewed on October 4, 2026.

  1. BSR guideline for management of systemic sclerosis (2024).
  2. ESVS guideline: acute limb ischemia (2020).
  3. EULAR systemic sclerosis treatment recommendations: 2023 update (published 2025).
  4. Hachulla et al. SEDUCE randomized trial (2016).
  5. Colonis intravenous iloprost: UK SmPC (updated September 4, 2025).
  6. Revatio: FDA-hosted US prescribing information.
  7. Adempas: US prescribing information.

Explore the full professional topic

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Rheumatology